Rinac Duo Tablet 2.5/500 mg
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Hanpung Pharmaceutical Co., Ltd.
MFDS item code 202009053 · Approved 2020.12.21
This product's status changed to Expired on 2025.12.21. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improves glycemic control in adults with type 2 diabetes mellitus
This medication is used to improve blood sugar control in adults with type 2 diabetes. It is administered when blood sugar control is difficult to achieve alone, alongside dietary and exercise therapy. It is suitable for patients with no previous experience of diabetes drug treatment and can be used to replace the combination of linagliptin and metformin. Additionally, it can be taken in combination with insulin when blood sugar control is insufficient with insulin and metformin therapy. It is also used to achieve better blood sugar control when added to the maximum dose of metformin combined with empagliflozin where the effect is inadequate. Overall, this medication is used to improve blood sugar control across various treatment combinations.
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication should be taken twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy whose blood glucose is not adequately controlled with monotherapy, the initial dose of this medication is 1 tablet of 2.5/500 mg twice daily. The dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take an initial dose equivalent to the doses of linagliptin and metformin they were previously taking. 3. Patients whose blood glucose is not adequately controlled with combination therapy with insulin and metformin: An initial dose of this medication similar to linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose should be considered. When this medication is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. The starting dose of metformin is 500mg or 850mg once daily; therefore, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function decreases to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately.
This medication consists of two ingredients: metformin and linagliptin, and is primarily used for the treatment of type 2 diabetes. This medication should not be used in patients with impaired renal function or those with lactic acidosis, diabetic ketoacidosis, or type 1 diabetes. Additionally, it should be avoided in cases of severe hepatic impairment or acute diseases that may affect renal function, including acute infections, dehydration, severe trauma, shock, acute myocardial infarction. It is also advisable not to administer this medication to pregnant or nursing women, nor to those with hypersensitivity. This medication may cause hypoglycemic symptoms; therefore, special attention should be paid to these symptoms when taking it in combination with sulfonylureas or insulin. A rare side effect called lactic acidosis may occur, which can worsen due to sudden deterioration of renal function, cardiopulmonary diseases, or sepsis; in such cases, you should stop taking the medication immediately and seek medical attention. Regular assessment of renal function should be conducted before and during treatment, especially in elderly patients or those with impaired renal function. Skin allergic reactions, such as acute pancreatitis and bullous pemphigoid, have also been reported, so immediate medical consultation is necessary if severe abdominal pain or skin blisters arise. This medication can reduce vitamin B12 levels, so it is important to check for vitamin B12 deficiency during long-term treatment and consider supplementation if necessary. Additionally, potential interactions with other medications should be discussed, particularly with medications that may affect renal function. During surgeries or radiological tests, this medication should be temporarily discontinued and resumed only after renal function has recovered post-surgery. Elderly patients are more prone to renal function decline, so it is advisable to start with the minimum dose and regularly monitor renal function. This medication has not been established for safety and efficacy in children and should not be used in this population. In cases of overdose, there is a risk of lactic acidosis, necessitating immediate medical treatment, and blood dialysis may be required. When storing this medication, keep it out of reach of children, protect it from moisture, and store it in its original container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. A temperature range of 1 to 30 degrees Celsius is recommended for room temperature storage. Proper storage will help maintain the medication's effectiveness for an extended period.
Bright yellow oval film-coated tablet
60 tablets/box [10 tablets/PTP×6]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Hanpung Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.